Regeneron Pharmaceuticals Inc (REGN)
Return on assets (ROA)
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net income (ttm) | US$ in thousands | 3,953,600 | 3,991,100 | 4,299,000 | 4,182,700 | 4,338,400 | 5,370,300 | 5,686,800 | 7,933,600 | 8,075,300 | 6,995,500 | 6,205,400 | 4,003,800 | 3,513,200 | 3,156,000 | 2,983,500 | 2,279,300 | 2,115,800 | 2,144,200 | 2,069,300 | 2,427,600 |
Total assets | US$ in thousands | 33,080,200 | 32,163,300 | 30,657,500 | 30,059,900 | 29,214,500 | 27,677,800 | 27,205,800 | 26,348,700 | 25,434,800 | 23,671,500 | 21,485,900 | 17,772,200 | 17,163,300 | 16,084,000 | 14,428,700 | 15,757,500 | 14,805,200 | 13,939,300 | 13,173,600 | 12,854,800 |
ROA | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% |
December 31, 2023 calculation
ROA = Net income (ttm) ÷ Total assets
= $3,953,600K ÷ $33,080,200K
= 11.95%
Regeneron Pharmaceuticals, Inc.'s return on assets (ROA) has shown a declining trend over the past eight quarters. The ROA decreased from 30.11% in Q1 2022 to 11.95% in Q4 2023. This significant decline indicates a decrease in the company's ability to generate earnings relative to its total assets.
The ROA peaked at 30.11% in Q1 2022, suggesting that the company was efficiently utilizing its assets to generate profits. However, the consistent decline in ROA since then may raise concerns about the company's asset management efficiency.
The average ROA over the past eight quarters is approximately 17.89%. A declining trend in ROA could indicate challenges in maintaining profitability or inefficiencies in asset utilization. Further analysis of the company's financial health, operational efficiency, and strategic decisions would be necessary to understand the underlying factors causing the decline in ROA.
Peer comparison
Dec 31, 2023
See also:
Regeneron Pharmaceuticals Inc Return on Assets (ROA) (Quarterly Data)